Neumora Therapeutics, Inc. (NMRA)
Nasdaq: NMRA · Biological Products, (No Diagnostic Substances) · Watertown, MA · filing with the SEC since 2021
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts in thousands. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Report filed | Mar 30, 2026 | Mar 3, 2025 | Mar 7, 2024 | · |
| Research and development | 176,065 | 200,927 | 142,719 | 91,749 |
| General and administrative | 60,091 | 62,537 | 45,475 | 31,121 |
| Total operating expenses | 241,156 | 263,464 | 252,098 | 135,870 |
| Operating income | -241,156 | -263,464 | -252,098 | -135,870 |
| Interest expense | 3,219 | 0 | · | · |
| Interest and investment income | 8,344 | 19,933 | · | · |
| Interest income (expense), net | 8,344 | 19,933 | 16,611 | 4,561 |
| Other income (expense), net | -767 | -78 | -170 | 405 |
| Total non-operating income (expense) | 4,358 | 19,855 | 16,441 | 4,966 |
| Income before income taxes | -236,798 | -243,609 | -235,657 | -130,904 |
| Income tax expense | 130 | 178 | 268 | · |
| Net income including non-controlling interests | -236,928 | -243,787 | -235,925 | -130,904 |
| Net income | -236,928 | -243,787 | -235,925 | -130,904 |
| Earnings per share, basic | -1.45 | -1.53 | -3.63 | -4.81 |
| Earnings per share, diluted | -1.45 | -1.53 | -3.63 | -4.81 |
| Weighted average shares, basic | 163,391 | 159,377 | 65,021 | 27,207 |
| Weighted average shares, diluted | 163,391 | 159,377 | 65,021 | 27,207 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding